Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
- Issued Date
- 2021
- Type
- Article
- Keyword
- Aged; 80 and over; Angiogenesis Inhibitors / adverse effects; Angiogenesis Inhibitors / pharmacokinetics; Angiogenesis Inhibitors / therapeutic use*; Biosimilar Pharmaceuticals / adverse effects; Biosimilar Pharmaceuticals / pharmacokinetics; Biosimilar Pharmaceuticals / therapeutic use*; Choroidal Neovascularization / diagnosis; Choroidal Neovascularization / drug therapy*; Choroidal Neovascularization / physiopathology; Double-Blind Method; Female; umansIntravitreal Injections; Macular Degeneration / diagnosis; Macular Degeneration / drug therapy*; Macular Degeneration / physiopathology; Male Middle Aged; Ranibizumab / adverse effects; Ranibizumab / pharmacokinetics; Ranibizumab / therapeutic use*; Recovery of Function; Therapeutic Equivalency; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A / antagonists &; inhibitors*; Vision; Ocular / drug effects*
- Publisher
- JAMA Ophthalmology
- Language
- 한국어
- ISSN
- 2168-6165
- Citation Volume
- 139
- Citation Number
- 1
- Citation Start Page
- 68
- Citation End Page
- 76
- 파일 목록
-
-
관련 파일이 존재하지 않습니다.
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.